David Feltquate - 29 Aug 2025 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Reporting relationship: Chief Medical Officer
Issuer ticker: ITOS
Reported as of: 29 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Aug 2025, 16:30:24 UTC
Prior SEC filing: 06 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Adi Osovsky, as Attorney-in-Fact

Key filing fact

David Feltquate filed Form 4 for iTeos Therapeutics, Inc. (ITOS) on 29 Aug 2025.

Key facts

This page summarizes David Feltquate's Form 4 filing for iTeos Therapeutics, Inc. (ITOS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Aug 2025, 16:30.

Change

Previous filing in this sequence was filed on 06 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002031518 Primary reporting owner

Feltquate David

Relationship: Chief Medical Officer
Address: C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN
Signature: /s/ Adi Osovsky, as Attorney-in-Fact
Signature date: 29 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ITOS transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -47,000
Change %: -100%
Price
Shares after: 0
Date: 29 Aug 2025
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David Feltquate is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company and thereafter, the Merger Sub merged with and into the Company (the "Merger"). The amount reported in Column 4 includes 47,000 restricted stock units of the Company ("Company Restricted Stock Units," and each such restricted stock unit, a "Company Restricted Stock Unit").

Footnote F2

(Continued from footnote 1) Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company and in accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an "Accelerated Vesting Restricted Stock Unit")

Footnote F3

(Continued from footnote 2) that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to $10.047 in cash per share and (y) one non-transferable contractual contingent value right per share.